NSCLC Clinical Trials in Stanford, California

4 studies are recruiting for nsclc in Stanford, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

   The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   52 in total

   Run by

   Ellipses Pharma

   See if you can join NCT05443126 on ClinicalTrials.gov

2. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

   The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   12 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT06051695 on ClinicalTrials.gov

3. Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

   The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Run by

   Maximilian Diehn

   See if you can join NCT04585490 on ClinicalTrials.gov

4. Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

   This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   3 in total

   Run by

   Joshua Palmer

   See if you can join NCT05987644 on ClinicalTrials.gov